Trials Sponsors Conditions Drugs Pricing

Conditions

Neuroblastoma

Keywords

NeuroblastomaDinutuximab BetaDNB

Outcome Measures

Primary Outcomes (1)

Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse.
This study is retrospective and consists of comparing two methods of treating neuroblastoma in two health establishments and covers the period from January 1, 1998 to December 31, 2023.
The period concerned is from January 1, 1998 to December 31, 2023.

Eligibility Criteria

Age2 Years - 25 Years

Sexall

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodProbability Sample

Study Population

Subjects aged 2 years to 25 years suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.

You may qualify if:

Subjects aged 2 years to 25 years

Sponsors & Collaborators

University Hospital, Strasbourg, France
Otherlead

Study Sites (1)

Service de Pharmacie - Stérilisation - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

Anne EL AATMANI, Pharm, PhDCONTACT33 3 88 12 78 06 Anne.ELAATMANI@chru-strasbourg.fr

Emilie BERTHON, Pharm, PhDCONTACT33 3 88 12 78 06 emilieberthon@orange.fr

Anne EL AATMANI, Pharm, PhDPRINCIPAL INVESTIGATOR

Emilie BERTHON, PhamD, PhDPRINCIPAL INVESTIGATOR

Sophie PERRIAT, PhamD, PhDPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Neuroblastoma

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors, Primitive, PeripheralNeuroectodermal Tumors, PrimitiveNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Central Study Contacts

Anne EL AATMANI, Pharm, PhD

CONTACT

33 3 88 12 78 06 Anne.ELAATMANI@chru-strasbourg.fr

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 1, 2024

First Posted

February 23, 2024

Study Start

November 28, 2023

Actual (reported)

Primary Completion

November 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Dinutuximab Beta at the HUS and the Toulouse Oncopole

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations